Tax sale and option grant for Travere (TVTX) chief legal officer

Rhea-AI Filing Summary

Travere Therapeutics' chief legal officer, Elizabeth E. Reed, reported routine equity compensation and a related tax sale. On 01/31/2026 she received 25,110 shares of common stock for $0 as restricted stock units settled, bringing her direct holdings to 115,380 shares. On 02/03/2026, 7,175 shares were sold at $32.12 solely to cover tax withholding on the vesting; the company’s plan requires this mandated “sell to cover” transaction, so it was not a discretionary trade. She also received an employee stock option on 01/31/2026 for 66,960 shares at an exercise price of $33.095, vesting 25% after one year and the remainder in 36 monthly installments, giving her 66,960 options directly held.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REED ELIZABETH E

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer and GC

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A(1)		25,110	A	$0	115,380	D
Common Stock	02/03/2026		S(2)		7,175	D	$32.12	108,205	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$33.095	01/31/2026		A		66,960		(3)	01/31/2036	Common Stock	66,960	$0	66,960	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

2. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

3. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Elizabeth E. Reed	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Travere Therapeutics (TVTX) report for Elizabeth E. Reed?

Travere Therapeutics reported that Chief Legal Officer Elizabeth E. Reed received 25,110 common shares via restricted stock units and 66,960 stock options. She also sold 7,175 shares strictly to cover tax withholding obligations related to vested RSUs, under a company-mandated “sell to cover” arrangement.

How many Travere Therapeutics (TVTX) shares does Elizabeth E. Reed now directly hold?

After these transactions, Elizabeth E. Reed directly holds 108,205 shares of Travere Therapeutics common stock. This figure reflects the RSU settlement on January 31, 2026 and the sale of 7,175 shares on February 3, 2026 to satisfy tax withholding requirements.

Was the Travere Therapeutics (TVTX) insider stock sale a discretionary trade?

The 7,175-share sale by Elizabeth E. Reed was not discretionary. It was mandated under Travere’s equity incentive plans to cover tax withholding on vested restricted stock units through a broker-facilitated “sell to cover” transaction designated by the company.

What are the details of Elizabeth E. Reed’s new Travere (TVTX) stock option grant?

Elizabeth E. Reed received an employee stock option for 66,960 Travere common shares at an exercise price of $33.095. One-fourth vests on the first anniversary of the January 31, 2026 grant date, and the remaining shares vest in 36 equal monthly installments thereafter.

What does each restricted stock unit represent in the Travere (TVTX) Form 4 filing?

Each restricted stock unit, as disclosed, represents a contingent right to receive one share of Travere Therapeutics common stock. Upon vesting and settlement, these units convert into actual shares, such as the 25,110 common shares credited to Elizabeth E. Reed on January 31, 2026.

How did the “sell to cover” transaction affect Elizabeth E. Reed’s Travere (TVTX) holdings?

The “sell to cover” transaction reduced Elizabeth E. Reed’s holdings by 7,175 shares to satisfy tax withholding on vested RSUs. After this mandated sale at $32.12 per share, her direct common stock holdings stood at 108,205 shares, according to the Form 4 data.